Ocular Therapeutix, Inc. (OCUL)
- Previous Close
4.2000 - Open
4.1400 - Bid 4.7300 x 600
- Ask 4.7600 x 600
- Day's Range
4.0600 - 4.7900 - 52 Week Range
1.9950 - 11.3100 - Volume
3,879,503 - Avg. Volume
2,467,368 - Market Cap (intraday)
705.235M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0200 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.50
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
www.ocutx.comRecent News: OCUL
Performance Overview: OCUL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCUL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCUL
Valuation Measures
Market Cap
705.24M
Enterprise Value
592.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.95
Price/Book (mrq)
7.74
Enterprise Value/Revenue
10.14
Enterprise Value/EBITDA
-8.93
Financial Highlights
Profitability and Income Statement
Profit Margin
-138.15%
Return on Assets (ttm)
-25.66%
Return on Equity (ttm)
-127.64%
Revenue (ttm)
58.44M
Net Income Avi to Common (ttm)
-80.74M
Diluted EPS (ttm)
-1.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
195.81M
Total Debt/Equity (mrq)
91.50%
Levered Free Cash Flow (ttm)
-49.44M